Document is current
Any future updates will be listed below
-
Authors
Yurdakul, Ozan
Alan, Abdulkarim
Krauter, Johanna
Korn, Stephan
Gust, Kilian
Shariat, Shahrokh F.
Hassler, Melanie R.
-
Funding
Funding for this research was provided by:
Austrian society for Urology and Andrology (AP01088OFF)
- License Information
-
More Information
Article History
Received: 29 July 2023
Accepted: 10 December 2024
First Online: 18 December 2024
Declarations
:
: The local ethics committee approved the study (EK-Nr: 1972/2021, Ethics Committee of the Medical University of Vienna). Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: SFS reports honoraria for lectures/consulting boards for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf Roche, Sanochemia, Sanofi, Takeda, Urogen; patents: method to determine prognosis after therapy for prostate cancer granted 2002-09-06, methods to determine prognosis after therapy for bladder cancer granted 2003-06-19, prognostic methods for patients with prostatic disease granted 2004-08-05 and soluble Fas urinary marker for the detection of bladder transitional cell carcinoma granted 2010-07-20. The other authors have no competing interests to declare that are relevant to the content of this article.The other authors have no competing interests to declare that are relevant to the content of this article.
